MktsMarkets

Aptevo Therapeutics Inc.
NASDAQ: APVOKey statistics
APVO News
Stories mentioning APVO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 3,924 | 3,535 | 4,044 | 3,328 | 3,633 | 3,880 | 3,103 | 3,643 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (6,837) | (5,996) | (7,610) | (6,226) | (6,480) | (6,382) | (5,213) | (6,024) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 140.00 | 190.00 | 61.00 | 22.00 | 72.00 | 70.00 | 112.00 | 141.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (6,697) | (5,806) | (7,549) | (6,204) | (6,408) | (6,312) | (5,101) | (5,883) |
| Earnings Per Share (Basic) | (6.41) | (18.37) | (2.23) | (8.40) | (1,582) | (6,312) | (357.86) | (1,237) |
| Earnings Per Share (Diluted) | (6.41) | (18.37) | (2.23) | (8.40) | (1,582) | (6,312) | (357.86) | (1,237) |
| Weighted Average Shares Outstanding (Basic) | 1,061 | 316.00 | 4,049 | 738.00 | 4.00 | 1.00 | 14.00 | 5.00 |
| Weighted Average Shares Outstanding (Diluted) | 1,061 | 316.00 | 4,049 | 738.00 | 4.00 | 1.00 | 14.00 | 5.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About APVO
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a stock listed on the Nasdaq Stock Market under the ticker symbol APVO. It last traded at $0.4500 (Nov 18, 2026, 4:00 PM ET), down 3.3% on the day. That gives Aptevo Therapeutics a market capitalisation of $1.5M.
Over the past 52 weeks APVO has traded between $0.4500 and $25.65.
For the quarter ended Mar 31, 2026 it reported a net loss of $6.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$6.7M |
| Dec 31, 2025 | — | -$5.8M |
| Sep 30, 2025 | — | -$7.5M |
| Jun 30, 2025 | — | -$6.2M |
From Aptevo Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…